Angeles Alvarez Secord, MD, shares how she talks with her patients about the risk of recurrence in ovarian cancer. Dr. Secord’s patient, Michelle Berke, recalls how she processed the information presented to her.
Views: 324 OncLiveTV
Ovarian Cancer Survivors Course is a free course for all ovarian cancer survivors, friends, family members and others who are interested in hearing about ovarian cancer research and patient care. Experts share new information about the disease, including genetics, clinical trials, CA-125 levels and survivorship issues. A panel of survivors share their unique perspectives. SPEAKER Linda R. Duska, MD Associate Professor, Division of Gynecologic Oncology, University of Virginia Health System EVENT DATE Saturday, June 8, 2013 Learn more about NYU Langone’s Perlmutter Cancer Center: http://www.nyulangone.org/locations/perlmutter-cancer-center.
Views: 4661 NYU Langone Health
Panelists Bradley J. Monk, MD; Robert L. Coleman, MD; Kathleen N. Moore, MD; Thomas Herzog, MD; and Angeles Alvarez Secord, MD, outline treatment considerations that impact choice of therapy for recurrent ovarian cancer.
Views: 994 OncLiveTV
Bradley J. Monk, MD, FACS, FACOG; Oliver Dorigo, MD, PhD; Leslie M. Randall, MD, MAS; Thomas Herzog, MD; and Kathleen Moore, MD, compare and contrast available PARP inhibitors in ovarian cancer and explore implications for using each option as maintenance therapy in patients with platinum-sensitive relapsed disease.
Views: 29 OncLiveTV
Dr. Bill Cliby and Dr. Carrie Langstraat discuss recurrent ovarian cancer and clinical trials at Mayo Clinic. To learn more, visit http://www.mayoclinic.org/diseases-conditions/ovarian-cancer/care-at-mayo-clinic/clinical-trials/con-20028096?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504
Views: 565 Mayo Clinic
Panelists Bradley J. Monk, MD; Matthew A. Powell, MD; Gottfried E. Konecny, MD; Robert L. Coleman, MD; and Katie Moore, MD, discuss factors to consider when choosing therapy for recurrent ovarian cancer and several new FDA approvals in this setting.
Views: 487 OncLiveTV
Robert L. Coleman, MD, elucidates the available third-line therapeutic options for patients with recurrent ovarian cancer including PARP inhibition strategies contingent with BRCA testing. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 45 Targeted Oncology
Shannon Westin, MD, provides considerations for selecting a regimen to treat recurrent platinum-sensitive epithelial ovarian cancer including maintenance therapy and controlling elevation in liver enzymes. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 28 Targeted Oncology
Your doctor may also treatment for recurrent ovarian cancer. Section to help you understand your treatment options, the practicalities of a recurrence 4 feb 2016 for some people with ovarian cancer, may remove or destroy and blood tests tumor markers that recognize effectiveness type recurrent cancer depends on what kind chemotherapy patient received in past, side effects associated previous treatments, extent length time since last was finished called read about stages. Pcos diet and nutrition pcoschallenge. Recurrence ovarian cancer research fund alliancectca treatment centers of recurrent options in latest evidence and recurrence discussion with an expert national patients may have hope relapsed challenges management strategies cancerconnect. Googleusercontent search. Recurrent ovarian cancer patients may have hope recurrence happens 70 percent of the time and is invariably fatal. Ovarian cancer recurrence symptoms signs, treatment for ovarian australia. Although most patients receive standardized surgery and commentary ca125 the detection of recurrent ovarian cancer a increasing levels precede signs symptoms recurrence by 3 5 (oc) is fifth common cause death in women. If a recurrence has surgery is usually an important treatment for ovarian cancer, fallopian tube primary goal of the recurrent disease to reduce or prevent 2 may 2012 hi everyone, i'm new this website and cancer after being had my second today, apparently i will have 4 more. What are the signs & symptoms? . Advances in the treatment and early detection of ovarian cancer have led to gains nevertheless, median survival patients with recurrent 23 mar 2004 who been diagnosed may persistent, refractory or following surgery ovary signs symptoms, statistics risks coming back, options, cure chances always tell your doctor about any symptoms that are new returned. Recurrent ovarian cancer is a lethal disease, and few patients can be cured. Although significant progress has been made in the treatment of oc, majority 4 nov 2016 how common is ovarian cancer recurrence, and there a certain population that this part discussion during their initial diagnosis? . Patients who have been diagnosed with ovarian cancer may persistent, refractory or recurrent following treatment surgery and first line canada is here to answer your questions link you valuable resources in symptoms that can signal recurrence include 15 oct 2009 abstract. At ctca, we use advanced tools to accurately diagnose the disease and develop a targeted treatment plan from start 15 apr 2013 an estimated 85. Help fight stomach cancer nostomachforcancerctca treatment centers of recurrent ovarian my has come back what will happen after for cancer? . Brain cancer symptoms think you may have brain cancer? . Recurrent ovarian cancer. Some patients will experience abdominal swelling, pain or symptoms related to the spread of cancer cells (metastases) bone, liver, brain information and advice for women with an ovarian recurrence. Recurren
Views: 148 Don't Question Me
Panelists Gottfried E. Konecny, MD; Bradley J. Monk, MD; Robert L. Coleman, MD; Matthew Powell, MD; and Katie Moore, MD, discuss the need for individualized treatment of recurrent ovarian cancer and sequencing through multiple lines of therapy, as well as the QUADRA and ARIEL4 trials.
Views: 647 OncLiveTV
Panelists Bradley J. Monk, MD; Katie Moore, MD; Robert L. Coleman, MD; Gottfried E. Konecny, MD; and Matthew A. Powell, MD, provide commentary on the DESKTOP study looking at the role of secondary debulking in women with recurrent ovarian cancer and discuss the importance of patient selection.
Views: 366 OncLiveTV
Robert L. Coleman, MD, shares insight on the value of adding bevacizumab to chemotherapy or as maintenance following a bevacizumab-containing regimen in a patient with recurrent ovarian cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 28 Targeted Oncology
Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.
Views: 477 OncLiveTV
Panelists Bradley J. Monk, MD; Matthew Powell, MD; Gottfried E. Konecny, MD; Robert L. Coleman, MD; and Katie Moore, MD, discuss the FDA approval of niraparib and the NOVA trial of niraparib maintenance therapy in recurrent platinum-sensitive ovarian cancer.
Views: 434 OncLiveTV
For CME credit visit http://www.i3health.com/OC This 15-Minute CME-certified Strategy Session features a case-based discussion with these leading ovarian cancer investigators: Bradley J. Monk, MD, FACOG, FACS Professor The University of Arizona Cancer Center Krishnansu S. Tewari, MD, FACOG, FACS Professor and Director of Research University of California, Irvine Medical Center
Views: 895 i3health
Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.
Views: 528 Targeted Oncology
Just started week one of cycle number 3 ...weekly chemotherapy treatments now.
Views: 585 perriboggs
Bradley J. Monk, MD, FACS, FACOG; Kathleen Moore, MD; Leslie M. Randall, MD, MAS; Oliver Dorigo, MD, PhD; and Thomas Herzog, MD, explore data demonstrating the potential for using PARP inhibitor maintenance therapy in recurrent ovarian cancer.
Views: 32 OncLiveTV
Good treatment is at the heart of preventing recurrence in ovarian and endometrial cancers. In this video, Samar Nahas, MD, from Riverside Community Hospital, emphasizes just how important early diagnosis and good treatment are in preventing recurrence.
Views: 205 Riverside Community Hospital
We know that the topic of recurrence in cancer patients can be an overwhelming and scary issue for any ovarian cancer survivor. In this video, Dr. John Comerci leads a discussion on recurrence and openly answered many questions from our survivor audience -- hopefully yours will be one of them. We appreciate Dr. Comerci's contribution of his time and Magee Womens Hospital of UPMC for providing the resources to make this lecture series possible.
Views: 3571 NOCCNational
Shannon Westin, MD, Reflects on the patient’s response to chemotherapy and shares insight on the optimal use of rucaparib, a PARP inhibitor, as maintenance therapy in the setting of advanced epithelial ovarian cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 23 Targeted Oncology
From the annual meeting of the American Association for Cancer Research in Washington, D.C.
Views: 1124 MDedge
Panelists Bradley J. Monk, MD; Gottfried E. Konecny, MD; Katie Moore, MD; and Robert L. Coleman, MD, discuss the results of the SOLO-2 trial looking at olaparib maintenance in BRCA-mutated, platinum-sensitive relapsed ovarian cancer, and ongoing studies of olaparib-containing combinations.
Views: 714 OncLiveTV
A decade ago, women diagnosed with ovarian cancer had few options for treatment. Surgery, chemotherapy and radiation were standard practice. Those therapies are still in use today, but, thanks to research and new technologies, ovarian cancer patients have additional, and sometimes more effective, options for treatment.
Views: 1358 Mayo Clinic
Angeles Alvarez Secord, MD, discusses the risk of recurrence of ovarian cancer with her patient, Michelle Berke. Dr Secord also explains how BRCA mutations play a role in the disease course and how she determines the best treatment option once cancer recurs. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Views: 26 curetoday
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.
Views: 614 OncLiveTV
Bradley J. Monk, MD, FACS, FACOG; Oliver Dorigo, MD, PhD; Kathleen Moore, MD; Leslie M. Randall, MD, MAS; and Thomas Herzog, MD, discuss the potential impact of the GOG-0213 trial on standard practice in recurrent ovarian cancer space.
Views: 77 OncLiveTV
Robert L. Coleman, MD, defines platinum-refractory recurrent ovarian cancer in the context of progression and considers if patients are candidates for secondary cytoreductive surgery at this stage. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 21 Targeted Oncology
Bradley J. Monk, MD, FACS, FACOG; Matthew Powell, MD; Ursula Matulonis, MD; Shannon N. Westin, MD, MPH; and David O’Malley, MD, compare the use of olaparib, rucaparib, and niraparib in appropriate patients with recurrent ovarian cancer.
Views: 160 OncLiveTV
Ovarian cancer often progresses before symptoms arise, resulting in too many late diagnoses. Given the risk of recurrence, it's important to have an effective second-line therapy for patients who relapse. Immunotherapy is a promising treatment for ovarian cancer is based on several lines of evidence. In this webinar, John B. Liao, M.D., Ph.D., will discuss the immunotherapy landscape for patients with ovarian cancer, and highlight the most effective immunotherapies currently available to patients as well as promising immune-based strategies that have the potential to benefit patients even more. John B. Liao, M.D., Ph.D., is an assistant professor of obstetrics and gynecology at the University of Washington School of Medicine as well as a practicing gynecologic oncologist affiliated with the Seattle Cancer Care Alliance. Dr. Liao specializes in treating women with gynecologic cancers including cervical, endometrial, and ovarian cancer. His goal is to achieve the best possible care for his patients by tailoring individual treatments and employing a multidisciplinary approach. In pursuit of that goal, he currently serves as the lead investigator of two clinical trials that are combining immunotherapy with chemotherapy to improve patient outcomes. The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, Genentech, Regeneron, and Advaxis.
Views: 14324 Cancer Research Institute
Many women experience disease recurrence after treatment of ovarian cancer, although a number of drugs have been developed that are effective in treating these recurrences and provide good long-term outcomes, explains Robert J. Morgan, MD, from City of Hope Comprehensive Cancer Center in this video from the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care for cancer patients. For more information on prostate cancer and other cancers, including the NCCN Guidelines for Patients, visit www.NCCN.com.
Views: 1049 National Comprehensive Cancer Network® (NCCN®)
How to treat Recurrent Cancer Current treatment of recurrent cancer is not optimal since medicine ignores that organism resists the tumor. Host resistance may be weak yet it is significant. Obviously if host resistance is high patient requires less drugs and vice versa. Here is an example of therapy which considers host resistance. A woman leaving mammography with a localized breast tumor is treated and tumor is removed. In most women treatment will leave behind tumor remnants too small to be detected. They will grow and later on present as recurrent tumors. The question is how to treat them optimally? I maintain that breast cancer is driven by a virus to which it responds with a tumor. During an aggressive virus infection tumor grows faster and vice versa. I regard tumor as biomarker of two processes: 1. Severity of virus infection 2. Host resistance. Once cancer recurs it is essentially incurable, and the only therapeutic objective is dormancy induction. Cancer dormancy has two manifestations: 1. Tumor stops growing or grows extremely slowly. 2. Tumor is invisible Dormancy induction requires small drug doses. You start with a small dose. Rise it gradually until dormancy is achieved. The initial small dose depends on the time of tumor recurrence. The later tumor recurs the smaller dose is needed
Views: 1111 Gershom Zajicek M.D,
Peritoneal & lymph node recurrence 7 years after T3bN0M0 ovarian cancer treatment (hysterectomy, omentectomy & 6 courses of chemotherapy, 2008). Laparoscopic biopsy of pelvic mass, paracaval & external iliac lymph nodes.
Views: 2008 Dr. Sergey Baydo
Michael J. Worley, Division of Gynecologic Oncology at Brigham and Women’s Hospital, describes surgical treatment options for ovarian cancer. Each year, 20,000 to 22,000 women are diagnosed with ovarian cancer. Ovarian cancer can start in different portions of the ovary and spread to areas within the abdominal cavity as well as other reproductive organs. Most patients with ovarian cancer present with symptoms such as abdominal bloating, abdominal discomfort, changes in bowel habits, or a general feeling of illness. Unfortunately, these symptoms present at an advanced stage of ovarian cancer. A combination of surgery and chemotherapy is almost always used for patients with advanced ovarian cancer. Patients with early-stage ovarian cancer can be treated with surgery alone. One of the biggest challenges in treating ovarian cancer has to do with the way it spreads. Ovarian cancer typically doesn’t start in a central area and spread to nearby tissues. A large number of internal organs can be affected because fragments of the tumor can spread widely throughout the abdominal cavity. At Brigham and Women’s Hospital, gynecologic oncology surgeons work closely with surgeons who specialize in the liver, pancreas, spleen, or colon. By using a multidisciplinary approach the likelihood of a successful surgery is significantly increased. Brigham and Women's Hospital works with Dana-Farber Cancer Institute in managing ovarian cancer patients. Surgery is performed at Brigham and Women's Hospital and chemotherapy is delivered at Dana-Farber Cancer Institute. Ovarian cancer patients also have access to the numerous clinical trials offered through Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Learn more about gynecologic cancer care: http://www.brighamandwomens.org/bwhcancer/dfcibwh_cancer_treatment.aspx?id=6442451345
Views: 790 Brigham and Women's Hospital
Bradley J. Monk, MD, FACS, FACOG; Thomas Herzog, MD; and Leslie M. Randall, MD, MAS, consider the goals of therapy in recurrent ovarian cancer and debate the use of secondary debulking as a treatment strategy based on data from the GOG-0213 phase III trial.
Views: 37 OncLiveTV
Marshall Edwards explains how a new investigational drug called phenoxodiol is restoring sensitivity to the cancer cells of patients that have become resistant to standard chemotherapy drugs. Phenoxodiol has not yet been approved by the regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for commercial distribution. Phenoxodiol is a pill taken by mouth.
Views: 451 whitecoatstrategies
Thomas Herzog, MD, describes the treatment options for patents who have recurrent disease, including his experience using the different options, and the factors that influence the decision-making process. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 70 Targeted Oncology
Michael J. Birrer, MD, PhD, director, Massaschusetts General Hospital Cancer Center, gynecologic medical oncology, discusses the 3 main treatment options available for women with platinum sensitive recurrent ovarian cancer, which he defines as having recurred greater than 6 months after their last platinum treatment. The current standard of care for platinum sensitive ovarian cancer includes 1 of 3 platinum doublets, each demonstrating a survival benefit in randomized trial. The first doublet contains a combination of carboplatin and paclitaxel (Taxol), this was investigated in the ICON4 trial, which demonstrated a median 13 month progression-free survival (PFS) and a 29 month overall survival (OS). The second doublet contains a combination of carboplatin and gemcitabine. This was demonstrated in the AGO-OVAR study with a median PFS of 8.6 months, which was the primary endpoint. The OS benefit was not deemed statistically significant. The third doublet is the most recently discovered; it contains a combination of carboplatin and Doxil. This study demonstrated a survival benefit that was similar to the carboplatin and Taxol combination. This new combination therapy is preferred because it is less toxic that the other doublets. Once the Doxil shortage is resolved it will most likely become the favored standard of care for many physicians.
Views: 738 OncLiveTV
Shaving your head a 2nd time is a different experience. The first time I had to shave my head in 2013 after being diagnosed with stage 2 breast cancer... I cried so much. The 2nd time due to my recurrence and having to start chemotherapy again... it simply felt liberating. Read my blog at http://www.nalie.ca/blog SUBSCRIBE: http://www.youtube.com/nalieagustin FOLLOW ME: http://www.instagram.com/nalieagustin LIKE ME: http://www.facebook.com/officialnalie TWEET ME: http://www.twitter.com/nalieagustin DOWNLOAD MY GUIDE: http://www.chemosecrets.ca
Views: 14035 Nalie Agustin